<p>GSK plc has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Exdensur (depemokimab). The approval covers its use as an add-on maintenance treatment for asthma in adults and adolescents aged 12 years and older with type 2 inflammation who are inadequately controlled on existing therapies, as well as for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) not adequately managed by systemic corticosteroids and/or surgery. Depemokimab demonstrated sustained efficacy and a favorable safety profile in multiple phase III trials. The medicine is also under regulatory review in the US, Japan, China, and the EU, with decisions expected from December 2025 through the first half of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on December 15, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

<p>GSK plc has received UK approval for Exdensur (depemokimab) as an add-on treatment for asthma and nasal polyps. The drug is approved for adults and adolescents with type 2 inflammation inadequately controlled by existing therapies. It showed efficacy and safety in phase III trials and is under review in the US, Japan, China, and the EU, with decisions expected by mid-2026.</p>

GSK Wins UK Approval for Exdensur Asthma and Nasal Polyp Drug